Trial
NCT05453396
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Washington
Collaborators
—
Condition
Recurrent B-Cell Non-Hodgkin Lymphoma
Intervention
Loncastuximab Tesirine
Why stopped
The trial closed early due to slow accrual.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-15